Establishment Labs Posts $72M in Q3 Revenue, Topping Q2's $67.5M
ESTA sits 45% above its 52-week low of $47 on elevated volume (1.8× avg).
Summary
Establishment Labs reported third-quarter revenue of $72 million, up 33.9% year-over-year and above the $67.5 million posted in Q2 2026. That extends the growth run that saw Q2 revenue rise 31.7% year-over-year to $67.54 million and beat the $65.77 million consensus. The sequential gain of roughly $4.5 million keeps the top line moving in the right direction after the company raised full-year guidance in August, and it now sees 2026 revenue of $274 million and an adjusted gross margin of about 70.7%. The quarter came with a pretax profit of USD -10.097 Million. The print lands with the stock at $68 and a market cap near $2 billion, so a revenue figure above the Q2 run rate is the number that matters for the growth story. The FDA's October approval of 28 additional Motiva implant sizes gives the sales base more room to expand into the fourth quarter.
At the time of this announcement, ESTA was trading at $68.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $47.00 to $97.59. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.